Jenburkt Pharmaceuticals Share Price

Jenburkt Pharmaceuticals

CMP as on23-May-22 15:17

₹ 570.55
13.7 2.46%

Open

₹ 564.90

Turnover (lac)

₹ 6

Prev. Close

₹ 556.85

Day's Vol (shares)

₹ 655

Day's Range

₹ 550.60
₹ 574.90

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 31-Jan-2022 - -
JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 inter alia to consider and approve the Unaudited Financial Results for the quarter and nine months ended on 31.12.2021. Standalone Unaudited Financial Results for the quarter and nine months ended on 31.12.2021. Standalone Unaudited Financial Results for the Quarter and Nine Months ended on 31st December, 2021 (As per BSE Announcement Dated on 11/02/2022)
Board Meeting - 14-Oct-2021 - -
Quarterly Results JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2021 ,inter alia, to consider and approve Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 26 October, 2021, at the Registered Office of the Company, inter alia, to take on record the unaudited financial results for the quarter and half year ended on 30 September, 2021. Unaudited Financial Results for the quarter and half year ended on 30.09.2021. (As per BSE Announcement Dated on 26/10/2021)
Board Meeting - 02-Aug-2021 - -
JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2021 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the quarter ended on 30.06.2021. Unaudited Financial Results for the quarter ended on 30th June, 2021. (As Per BSE Announcement dated on 12.08.2021)
Board Meeting - 23-May-2021 - -
JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2021 ,inter alia, to consider and approve 1. audited financial statements for the quarter and financial year ended 31st March, 2021 2. To consider a proposal to acquire a land in the state of Gujarat. to set up a modern pharmaceutical formulations manufacturing unit and 3. To consider a proposal to begin on pilot scale to sell certain Healthcare products via digital marketing. Jenburkt Pharmaceuticals Ltd has informed BSE that a Meeting of the Board of Directors of the Company is scheduled to be held on June 02, 2021, inter alia, to take on record the audited financial results for the quarter and financial year ended on March 31, 2021 and to consider recommendation of Dividend, if any. Further, the Board will also consider: 1. To consider a proposal to acquire a land in the state of Gujarat, to set up a modern pharmaceutical formulations manufacturing unit and authorize Director to take necessary steps in respect of the same. 2. To consider a proposal to begin on pilot scale to sell certain Healthcare products via digital marketing. With reference to Companys letter dated March 31, 2020, submitted with the Exchange, on the same day, the notional trading window is closed from April 01, 2021 up to 48 hours after the completion of Board Meeting scheduled on June 02, 2021. JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2021 ,inter alia, to consider and approve Clarification: Kindly note that in earlier communication to the exchange, dated 23rd May, 2021, in the subject line the date of ensuing Board Meeting was erroneously mentioned as 6th June, 2021 instead of 2nd June, 2021. However, the Companys letter attached thereto, carried the actual date of 2nd June, 2021,which please be noted. The Board Meeting is scheduled on Wednesday, 02nd June, 2021. (As Per BSE Announcement Dated on 24.05.2021)
Board Meeting - 24-May-2021 - -
Dividend & Audited Results Jenburkt Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 02, 2021, inter alia, have recommended a dividend of Rs.10.20 (102%) per equity share of Rs.10/- each on 4589378 equity shares of the Company. 1. The Audited Financial Statements for the quarter and financial year ended on 31st March, 2021, on the recommendation of Audit Committee, vide its meetings held on even date. 2. A dividend of Rs.10.20 (102%) per equity share of Rs.10/- each on 4589378 equity shares of the Company. 3. Appointment of Shri Ashish U. Bhuta (DIN: 00226479) as a director on the Board of the Company, on rotation basis. 4. Re-appointment of Shri Dilip H. Bhuta (DIN: 03157252) as the Whole Time Director of the Company for a period of five years and his terms of remuneration for a period of three years, from 1st April, 2022. 5. To acquire land(s) in the state of Gujarat, to set-up a modern pharmaceutical formulations manufacturing unit and authorizing directors to take necessary steps, in this regard. 6. To begin on pilot scale to sell certain Healthcare products via digital marketing. 7. To schedule the Companys 36th Annual General Meeting on Tuesday, 07th September, 2021. (As Per BSE Announcement Dated on 02.06.2021) Newspaper publications of Audited Financial Results for the quarter and financial year ended on 31st March, 2021. (As Per BSE Announcement Dated 03.06.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity